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Abstract 
Background:  Reactive hyperaemia induces a slowing of pulse wave velocity (PWV) in conduit arteries 
of healthy subjects (flow-mediated slowing [FMS]).  This could be an alternative method for assessing 
peripheral vasomotor function to the gold standard method of flow-mediated dilatation (FMD) a more 
expensive and technically demanding technique. We aimed to assess the reproducibility of FMS in 
healthy participants and to test its ability to detect differences in vasomotor function in patients with 
familial hypercholesterolaemia (FH) and post lipoprotein apheresis (LA) treatment.  
Methods: 25 healthy participants were studied on two occasions to assess reproducibility of FMS.  In a 
case control study of 22 patients with FH and matched healthy controls FMD and FMS were compared. 
An intervention study in 12 patients with FH looked at the impact of a single LA treatment on FMS 
assessed pre and post treatment.  
Results: FMS demonstrated good reproducibility (coefficient of variation [CoV] 7.3%).  Patients with FH 
had reduced FMS in comparison to matched healthy controls (C) (FMS% FH -15.13 ± 5.04% vs C -18.41 
± 5.15%  p=0.023), with no difference in FMD% between the two groups.  A single LA treatment 
significantly improved FMS (pre -18.81 ± 9.84 vs post -24.09 ± 7.61% p=0.016). 
Conclusions: FMS is a reproducible technique, which is able to detect differences in vasomotor function 
both in a condition associated with endothelial dysfunction and following an acute intervention known to 
improve endothelial function. This simple technique has potential for accessible assessment of vasomotor 
function in clinical studies. 
Word count: 245 
Keywords: endothelium, vasodilatation, hyperaemia, pulse wave velocity  
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Introduction 
The current gold standard method for the non-invasive assessment of endothelial function uses ultrasound 
to measure flow-mediated dilatation (FMD) mediated by the release of endothelium derived vasodilators 
such as nitric oxide (NO).  This technique, which has good reproducibility within expert vascular 
laboratories, requires high levels of operator training, is technically demanding and relatively expensive 
to set up.  It is possible to use FMD in large scale population studies,
1, 2
 although, this can be expensive 
and logistically challenging. Other potentially simpler methods are available but their reproducibility and 
clinical relationships to endothelial function are less well defined and validated.
3
 One new technique 
based on measuring changes in pulse wave velocity (PWV) in the brachio-radial arterial tract following a 
standard reactive hyperaemic (RH) stimulus was first demonstrated by Naka et al.
4
 This method used 
pressure transducers, attached to non-occlusive cuffs positioned around the brachial and radial arteries, to 
measure PWV. RH was generated by a 5-minute period of forearm ischaemia via inflation of a cuff 
located at the wrist to 250 mmHg. The resultant reduction in vascular tone led to a flow-mediated slowing 
in PWV which could be measured, and the change from baseline calculated. 
Development of the software and equipment for this system, now consisting of a small box and a 
laptop computer has made it highly portable. Thus, it potentially lends itself to use in the community 
and/or in larger studies where it is more challenging to assess FMD, whilst also favouring use by non-
specialist investigators. However, applicability of a new method depends on its reliability, its ability to 
characterize the impact of disease and its progression on the vasculature and to evaluate the effect of 
interventions.  We therefore aimed to assess the reproducibility of this technique and its ability to detect 
differences in vasomotor function in patients with familial hypercholesterolaemia (FH) and following an 
acute intervention (lipoprotein apheresis [LA]).  
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Methods 
All participants were treated in accordance with the Declaration of Helsinki and provided informed 
consent for the study.  The South East Wales Research Ethics Committee Panel B (ref: 09WSE0238) 
approved the study. 
Study 1 Reproducibility:  25 healthy adults aged 21 to 37 years were studied to assess the reproducibility 
of changes in PWV for flow-mediated slowing (FMS).  All subjects were non-smokers and attended 
having fasted and avoided caffeine for at least four hours. The study was carried out in a temperature-
controlled laboratory at the Wales Heart Research Institute. Participants attended on two occasions at the 
same time of day. FMS and FMD were assessed concurrently 
Study 2 FH versus controls:  22 patients aged 28 to 65 years with FH (defined by the Simon Broome 
criteria) and 22 age and gender matched controls were studied.
5
 All subjects were non-smokers and 
attended having fasted and avoided caffeine for at least four hours. FH patients receiving vasoactive 
medications were asked to withhold these on the morning of the study. The study was carried out in a 
temperature-controlled laboratory at the Wales Heart Research Institute. FMS and FMD were assessed 
concurrently 
Study 3 Effect of lipoprotein apheresis (LA) in FH on FMS: 12 patients aged 41 to 76 years undergoing 
LA treatment were assessed to see whether a change in FMS was detectable following a single apheresis 
session.    Patients were non-smokers and attended for LA as clinically scheduled, having fasted and 
avoided caffeine for at least four hours. Those taking vasoactive medications were asked to withhold 
these on the day of study. The study took place in a temperature controlled laboratory at the Lipid Unit at 
University Hospital Llandough. LA treatment was undertaken using three systems according to patient 
tolerability and clinical requirements, polyacrylate whole blood adsorption (DALI® n = 8), whole blood 
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dextran sulfate adsorption (n = 1), or plasma dextran sulfate adsorption (n = 3), as previously described.
6
 
FMD was not assessed concomitantly in study 3 due to time, equipment and space limitations 
 
Vascular function assessment 
Flow-mediated slowing. FMS was assessed using a Vicorder device (Skidmore medical, Bristol, UK). 
Participants rested supine on a bed, with their right arm positioned 70-80
o
 to their body.  Two Hokanson 
SC5 cuffs were placed around the upper arm and just above the wrist.  A third cuff was positioned around 
the forearm just below the medial epicondyle and used to occlude the forearm for 5 minutes (see appendix 
1).  The distance between the two PWV cuffs was measured mid cuff to mid cuff and entered into the 
Vicorder.  Baseline PWV was recorded every 15-20 seconds for 5 minutes by inflating the cuffs to 
65mmHg and deflating after several seconds, once a PWV reading was registered. Following a 5-minute 
cuff occlusion at 250mmHg PWV was recorded for a further 10 minutes. PWV readings from the first 
five minutes were averaged for baseline PWV.  The lowest PWV measured within two and a half minutes 
of release of the occlusion cuff was taken for calculating the maximum change in PWV.  In addition, the 
PWV at 1 min post hyperaemia was also noted.  Change in PWV was calculated as absolute change, 
(minimum PWV- baseline PWV) or percentage change ([absolute change/ baseline PWV] x100).   
 
Flow-mediated dilatation. FMD was assessed using high resolution ultrasound (ALOKA prosound 5500) 
according to a standard protocol. A detailed description is in appendix 1 but briefly, dilatation of the right 
brachial artery during RH was assessed following a 5 minute forearm cuff occlusion. FMD was expressed 
as maximal change in diameter post-RH expressed both as percentage and absolute changes. Changes in 
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blood flow were also measured and RH was expressed as a percentage change between baseline and peak 
velocity time integral (VTI).   
Statistical analysis 
Data are presented as mean ± SD. Within method reproducibility is expressed as the percentage of the 
coefficient of variation [(SD of the paired differences/the overall mean) √2). Data are also presented as 
Bland-Altman plots.  Relationships between FMS and FMD responses were explored using Pearson and 
Spearman correlations having used the Shapiro-Wilk test to check for normality.  Independent samples t-
test or the independent samples Mann-Whitney U test were used to assess differences in responses 
between FH and matched controls.  Paired t-tests or related samples Wilcoxon-signed rank test were used 
to compare responses before and after LA. All tests were two-sided and p-values of <0.05 were viewed as 
significant. SPSS version 20 was used for the statistical analysis.  
Results 
Study 1 Reproducibility study 
Baseline VTI and reactive hyperaemia were similar on the two visits (BL VTI V1 0.045 ± 0.016m & V2 
0.042 ± 0.016m p=0.34, RH% V1 715 ± 187% & V2 752 ± 229% p=0.42). 
  Baseline PWV was similar between the two visits and highly reproducible (Table 1).  Maximal 
change in PWV following release of the occlusion cuff had a coefficient of variation (CoV) below 10%, 
whereas, change in PWV measured at 1 minute post cuff release had CoVs closer to 20% whether 
expressed as percentage or absolute change.  Interestingly, the CoV for FMS was smaller than the CoV 
for FMD assessed concurrently in the same arm.   
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Bland-Altman plots also show good agreement between the two visits for baseline PWV, 
minimum PWV, absolute change and percentage change in PWV (Figure 1). 
Except for an association between max FMSABS and FMDABS at visit 2 (r=-0.45 p= <0.05) there 
was no consistent correlation between FMS and FMD assessed concurrently.  
Study 2 Familial Hypercholesterolaemia vs controls  
Baseline PWV was similar between the two groups (C 8.2 ± 0.9m/s vs FH 7.7 ± 0.8m/s p=0.12). FMS 
was greater in the healthy controls than in the FH patients, whether expressed as a percentage or absolute 
change in PWV post reactive hyperaemia (FMS% C -18.4 ± 5.2% vs FH -15.1 ± 5.0% p=0.023 & 
FMSABS C -1.5 ± 0.5m/s vs FH -1.2 ± 0.5m/s p=0.023) (Figure 2a).   
There was no difference between the baseline arterial diameter for the two groups (FH 3.59 ± 
0.60mm vs C 3.56 ± 0.61mm p=0.86).  Baseline velocity time integral and reactive hyperaemia were 
similar between the two groups (baseline VTI FH 0.045 ± 0.010m vs C 0.042 ± 0.015m p=0.54 & RH% 
FH 796 ± 159% vs C 816 ± 234%  p=0.74). FMD was not significantly different between FH patients and 
the age and gender matched controls when assessed concurrently with FMS in the same arm (Figure 2b). 
 
Study 3 Effect of lipoprotein apheresis on FMS in patients with familial hypercholesterolaemia  
LA significantly reduced total cholesterol (pre 6.05 ± 1.57mmol/L, post 2.72 ± 0.84mmol/L  p=<0.001), 
LDL (pre 4.08 ± 1.44mmol/L, post 1.37 ± 0.65mmol/L  p=0.002) , HDL (pre 1.15 ± 0.47mmol/L, post 
0.94 ± 0.0.46mmol/L  p=0.002) and triglycerides (pre 1.77 ± 0.57mmol/L, post 0.89 ± 0.34mmol/L  
p=<0.001).  Baseline PWV did not change following LA (pre 8.8 ± 1.2m/s vs post 9.2 ± 1.2m/s, p=0.19).  
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FMS was greater after LA when expressed both as a percentage or absolute change in PWV (FMS% pre    
-18.8 ± 9.8% vs post -24.1 ± 7.6% p=0.016 & FMSABS pre -1.7 ± 0.9m/s vs post -2.2 ± 0.9m/s p=0.015).  
 
Discussion 
In this study we have demonstrated that FMS is a reproducible method for assessing vasomotor function, 
can detect vasomotor dysfunction in patients with familial hypercholesterolaemia and can also detect an 
improvement in vascular function following a single lipoprotein apheresis treatment. 
The technique of assessing changes in PWV following reactive hyperaemia was initially 
developed by Naka et al.
4
  They found that PWV was decreased after a 5-minute forearm occlusion 
period.  They also demonstrated the influence of NO on PWV by showing that PWV increased 
concomitantly with a decrease in brachial artery diameter when the nitric oxide synthase inhibitor L-N
G
-
monomethyl Arginine citrate (L-NMMA) was infused into the arm, whereas stimulation of NO release by 
acetylcholine caused a decrease in PWV whilst brachial artery diameter increased. This suggests that this 
technique is a potential marker of brachial artery endothelial function, in keeping with findings from 
studies demonstrating reduction of FMD following L-NMMA infusion, despite maintained reactive 
hyperaemia.
7, 8
 
Technical development of the system used for assessing PWV has made it very portable, which 
together with its ease of use suggests considerable potential for its application beyond the specialist 
vascular physiology research laboratory setting, where use of the current gold standard method of FMD, 
although possible, is considerably more challenging.  Although the Vicorder method of assessing PWV 
has been shown to be reproducible, there has been little information on the reproducibility of using this 
device for assessing dynamic vasomotor function.
9
 Before endorsing any new method for wider 
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application, it is not only important for it to be technically and practically feasible but it is also essential 
to understand the reproducibility/variability of the method in the investigators’ hands.   We therefore 
undertook this study to demonstrate the reproducibility of the method for assessing vasomotor function.  
Notably, in our preliminary work using the method of Naka et al, we were unable to detect a significant 
fall in PWV with the RH stimulus provoked by positioning the occlusion cuff at the wrist
4
.  We therefore 
repositioned the occlusion cuff to just below the medial epicondyle to increase the ischaemic territory, 
thus, provoking a greater hyperaemic stimulus. This produced a readily detectable reduction in PWV 
post-RH. 
FMS was shown to be very reproducible for both maximal percentage and absolute changes in 
PWV (CoV 7.3% & 8.2% respectively).  Measures of maximal change in FMS were more reproducible 
than readings taken at 1-minute time point post cuff release (CoV 17.2%).  The reproducibility of this 
FMS method was superior to that of FMD acquired simultaneously using ultrasound in our study. Despite 
a very good coefficient of variation for measurement of baseline diameter (CoV 2.2%), FMD had 
relatively poor reproducibility when expressed as both absolute and percentage change in diameter (CoV 
28.1% & 26.6% respectively).  Importantly, this is probably due to concurrent assessment of FMS and 
FMD in the same arm with resultant movement of the artery and surrounding muscles caused by the 
inflation and deflation of the cuffs used for assessment of FMS limiting the accuracy of measurement of 
arterial diameter by ultrasound during hyperaemia.  In another study, Donald et al, showed a CoV of 7.1% 
for FMD which is comparable to our FMS method.
3
  In this study FMD had superior reproducibility to 
other non-invasive methods of assessing endothelial function (changes in pulse wave analysis and pulse 
contour analysis following inhalation of salbutamol).  In our study, FMS also had smaller coefficients of 
variation than these alternative methods (pulse wave analysis CoV 11.5%) and pulse contour analysis 
CoV 18.2%), demonstrating its potential for use as a measure of vasomotor function.
3
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Another non-invasive method for assessment of vasomotor function is reactive hyperaemia pulse 
amplitude tonometry (RH-PAT). This simple technique measures changes in fingertip pulse amplitude 
following a hyperaemic stimulus, giving a reproducible measure of microvascular function in part 
mediated by NO.
10, 11
  RH-PAT is associated with FMD although heterogeneity between results has been 
noted.
12, 13
 As FMS is a measure of conduit-vessel function we might expect some differences between 
FMS and RH-PAT which together could provide easily accessible and complementary insights into 
vascular status.   
Previous studies have assessed the reproducibility of the change in PWV following a reactive 
hyperaemic stimulus and have demonstrated good CoV%. 
14, 15
  However, these studies have used 
different methods for assessing PWV (applanation tonometry and mechanotransducers) and have 
measured PWV from the carotid to the radial arteries. 
14, 15
   Additionally, there are differences between 
these studies in the positioning of the occlusion cuff; Kamran et al used an upper arm occlusion cuff 
placement, whereas Graf et al place the occluding cuff on the forearm, as did we. 
14, 15
  Therefore, ours is 
the first study to look at the reproducibility of a cuff-based method for assessing the change in PWV in 
the brachial artery in response to hyperaemia. The lack of association between FMD and FMS parameters  
agrees with previous findings by Dhindsa et al and could indicate different influences of mechanical and 
physiological changes on diameter and stiffness of the vessels walls.
16
   
We found that FMS could identify vasomotor dysfunction in a group of FH patients compared 
with matched controls, consistent with previous work demonstrating endothelial dysfunction in adults and 
children with dyslipidaemia. 
17, 18
  That a difference was not seen with FMD could be due to confounding 
mechanical effects of concurrently assessing PWV during cuff inflation with lower reproducibility of 
FMD in this setting impairing detection of differences between groups.  Alternative reasons could be that 
13 
 
the two techniques assess different pathways, and possibly differential confounding influences of disease 
processes and/or treatments.
19
  
LA has previously been shown to improve endothelial function in both the microvasculature and 
coronary circulation. 
20, 21
  Our study is the first to demonstrate an improvement in peripheral conduit 
artery vasomotor function and is consistent with these previous findings.  Although Stadler et al found no 
change in FMD post LA in 6 patients; their study was probably underpowered to detect a modest 
difference. 
22
  Due to time and space constraints we were unable to evaluate FMD concurrently in this 
protocol.  
There are some limitations with this study. We did not compare the responses of the two 
techniques to an independent NO-donor such as glyceryl trinitrate (GTN). However, Naka et al had 
previously demonstrated that the decrease in PWV in response to GTN administration was similar 
between patients with coronary heart disease and normal subjects.
4
 The main aim of this study was to 
compare FMD with FMS as a practical measure of vasomotor function in response to hyperaemia, which 
is more consistently associated with cardiovascular  pathophysiology and response to prognostically 
beneficial therapies than endothelium-independent vasodilator responses to NO donors.
23
   
Repositioning the occluding cuff proximally to the lower measurement cuff may influence the 
mechanisms underpinning the changes in vascular tone, as has been demonstrated in FMD studies using 
different occlusion cuff positions. 
7
  This could mean that whilst FMD is predominantly mediated by NO, 
other factors may contribute to the FMS phenomenon. Assessing FMS following an infusion of L-
NMMA could allow determination of the extent to which the observed reduction in PWV in response to 
hyperaemia is NO-mediated.   
A limitation of the FMS technique itself is the lack of assessment of blood flow.  However, we 
know from previous studies that there are rarely significant differences in RH between groups with or 
14 
 
without risk factors for arterial disease, as we found in study 2, or following a short-medium term 
intervention. However, this might not be the case in those with more advanced diabetes and 
cardiovascular disease. Therefore, the FMS technique is probably less appropriate for detailed 
mechanistic evaluation of vascular function, especially in groups with advanced diseases.   As a 
technique, FMS could be useful as a global indicator of vasomotor function suitable for evaluation of 
large-scale populations and early stage disease cohorts.  Its practical ease and low cost, with consequent 
potential scalability, could more than make up for the lack of RH-data. Smaller or nested studies using 
FMD or even invasive arterial physiological assessment, within such studies could be included to 
determine in more detail any influence of hyperaemia and potential underlying mechanistic pathways, 
should this if of interest.  
Finally, the patients in the apheresis study were treated with three different methods for 
lipoprotein apheresis. Due to the limited number of patients available, it was not possible to investigate 
here whether these specific methodologies might have a differential impact on vascular function. 
In conclusion FMS is a reproducible method for the assessment of vasomotor function and is 
sensitive enough to detect differences in vascular function in disease and following an intervention. This 
simple and reliable technique is a potentially cheaper and more accessible means to assess vasomotor 
function. It should lend itself well to large population and field studies, including use beyond the 
specialist vascular laboratory.   It is not intended as a replacement for FMD or other established methods 
but to provide clinically relevant and complementary information regarding vascular function.  
 
  
15 
 
Acknowledgements 
The authors would like to thank Dr I McDowell, Dr S Zouwail, Rhiannon Edwards (CNS) & Dr P 
Ashfield-Watt for their assistance in recruiting patients for the FH study, along with the team in the Lipid 
Unit who helped with the LA study. 
Conflict of interest: None declared. 
Funding: This research was in part supported by an equipment grant from the Heart Research Fund for 
Wales. 
 
16 
 
References 
1. Donald AE, Charakida M, Falaschetti E, et al. Determinants of vascular phenotype in a large 
childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC). Eur Heart J 
2010;31:1502-10. 
2. Skaug E-A, Aspenes ST, Oldervoll L, et al. Age and gender differences of endothelial function 
in 4739 healthy adults: the HUNT3 Fitness Study. Eur J Prev Cardiol 2013;20:531-540. 
3. Donald AE, Charakida M, Cole TJ, et al. Non-Invasive Assessment of Endothelial Function: 
Which Technique? J Am Coll of Cardiol 2006;48:1846-1850. 
4. Naka KK, Tweddel AC, Doshi SN, et al. Flow-mediated changes in pulse wave velocity: a new 
clinical measure of endothelial function. Eur Heart J 2006;27:302-9. 
5. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering 
Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-896. 
6. Lee W, Datta B, Ong B, et al. Defining the Role of Lipoprotein Apheresis in the Management of 
Familial Hypercholesterolemia. Am J Cardiovasc Drug 2011;11:363-370. 
7. Doshi SN, Naka KK, Payne N, et al. Flow-mediated dilatation following wrist and upper arm 
occlusion in humans: the contribution of nitric oxide. Clin Sci 2001;101:629-635. 
8. Joannides R, Haefeli WE, Linder L, et al. Nitric Oxide Is Responsible for Flow-Dependent 
Dilatation of Human Peripheral Conduit Arteries In Vivo. Circulation 1995;91:1314-1319. 
9. Naka KK, Tweddel AC, Parthimos D, et al. Arterial distensibility: acute changes following 
dynamic exercise in normal subjects. Am J Physiol Heart Circ Physiol 2003;284:H970-8. 
10. Noon JP, Haynes WG, Webb DJ, et al. Local inhibition of nitric oxide generation in man reduces 
blood flow in finger pulp but not in hand dorsum skin. J Physiol 1996;490:501-508. 
11. Bonetti PO, Barsness GW, Keelan PC,et al. Enhanced external counterpulsation improves 
endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 
2003;41:1761-1768. 
12. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function 
with finger arterial pulse wave amplitude. Am Heart J 2003;146:168-174. 
13. Cornelissen VA, Onkelinx S, Goetschalckx K, et al. Exercise-based cardiac rehabilitation 
improves endothelial function assessed by flow-mediated dilation but not by pulse amplitude tonometry*. 
Eur J Prev Cardiol 2014;21:39-48. 
14. Kamran H, Salciccioli L, Eun Hee K,et al. Effect of Reactive Hyperemia on Carotid-Radial 
Pulse Wave Velocity in Hypertensive Participants and Direct Comparison With Flow-Mediated Dilation: 
A Pilot Study. Angiology 2010;61:100-106. 
15. Graf S, Valero MJ, Craiem D, et al. Temporal pattern of pulse wave velocity during brachial 
hyperemia reactivity. J Phys: Conf Ser 2011;313. 
16. Dhindsa M, Sommerlad SM, DeVan AE, et al. Interrelationships among noninvasive measures 
of postischemic macro- and microvascular reactivity. J Appl Physiol 2008;105:427-432. 
17. Sorensen K, Celermajer D, Georgakopoulos D, et al. Impairment of endothelium-dependent 
dilatation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein 
(a) level. J Clin Invest 1994;93:50-5. 
18. Donald AE, Halcox JP, Charakida M,et al. Methodological Approaches to Optimize 
Reproducibility and Power in Clinical Studies of Flow-Mediated Dilation. J Am Coll Cardiol 
2008;51:1959-1964. 
19. Reriani MK, Dunlay SM, Gupta B,et al. Effects of statins on coronary and peripheral endothelial 
function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J 
Cardiovasc Prev and Rehabil 2011;18:704-716. 
17 
 
20. Tamai O, Matsuoka H, Itabe H, et al. Single LDL Apheresis Improves Endothelium-Dependent 
Vasodilatation in Hypercholesterolemic Humans. Circulation 1997;95:76-82. 
21. Mellwig KP, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity 
through single LDL apheresis. Atherosclerosis 1998;139:173-178. 
22. Stadler RW, Ibrahim SF, Lees RS. Peripheral vasoactivity in familial hypercholesterolemic 
subjects treated with heparin-induced extracorporeal LDL precipitation (HELP). Atherosclerosis 
1997;128:241-249. 
23. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial Function and Dysfunction: Testing and 
Clinical Relevance. Circulation 2007;115:1285-1295. 
  
18 
 
Legends 
Figure 1.  Bland-Altman plots for baseline PWV, minimum PWV post cuff release, absolute change in 
FMS and percentage change in FMS.  
 
Figure 2.  Result for FMS (a) and FMD (b) expressed as a percentage change, comparing patients with 
FH with age and gender matched healthy controls.  Results are mean ± SEM. 
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Table 1. Summary of FMS and FMD data for visits 1 and 2 
 
  Visit 1 Visit 2 p-value CoV% 
Baseline PWV (m/s) 7.64 ± 1.05 7.53 ± 0.91 0.37 3.3 
 
  
   Max FMSABS (m/s) -1.60 ± 0.58 -1.60 ± 0.42 0.99 8.2 
Max FMS% (%) -20.66 ± 6.02  -21.12 ± 4.32 0.55 7.3 
  
    1 min  FMSABS (m/s) -1.19 ± 0.59 -1.27 ± 0.43 0.47 18.4 
1 min FMS% (%) -15.22 ± 6.33 -16.95 ± 5.35 0.25 17.2 
  
    Baseline Diameter (mm) 3.85 ± 0.72 3.84 ± 0.71 0.71 2.2 
FMDABS (mm) 0.16 ± 0.12 0.17 ± 0.11 0.58 28.1 
FMD% (%) 4.31 ± 3.36 4.55 ± 3.14 0.55 26.6 
 
CoV%, coefficient of variation;  PWV, pulse wave velocity; Max, maximum change in PWV post 
occlusion cuff release FMSABS, flow-mediated slowing expressed as absolute change in pre and post 
occlusion PWV; FMS%, flow-mediated slowing expressed as percentage change; 1 min, change in PWV 1 
minute post occlusion cuff release; FMDABS, flow-mediated dilatation expressed as absolute change in pre 
and post occlusion artery diameter; FMD%, flow-mediated dilatation  of the brachial artery expressed as a 
percentage change.  
 
